Table 1. . Summary of key findings from retrospective analyses of patients with pre-existing autoimmune conditions treated with checkpoint inhibitors for advanced melanoma.

Study	Number of patients	Type of checkpoint inhibitor	% patients experiencing AD flare	% patients experiencing irAE (grade ≥3)	% patients with AD flare or grade ≥3 irAE	% patients with death associated with AD flare or irAE	% patients with discontinuation of therapy due to flare/irAE
Johnson et al.	30	Anti-CTLA-4	27	33	50	3	not reported
Menzies et al.	52	Anti-PD-1	38	10	48	0	12
Gutzmer et al.	19	Anti-PD-1	42	5	47	0	0

AD: Autoimmune disease; CTLA: Cytotoxic T-lymphocyte antigen; irAE: Immune-related adverse event; PD-1: Programmed cell death 1.